Advertisement
Advertisement

Quality Assurance/Quality Control

Advertisement

FDA Announces Reopening of Comment Period Regarding HCP Immunogenicity Risk from Follow-on Recombinant Peptides

January 03, 2025

The comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, has been reopened by FDA until March 3, 2025.

Specification Equivalence—A Practical Approach

December 30, 2024

In this first of a four-part series, the authors provide an introduction to a practical approach for establishing specification equivalence. The regulatory basis and compliance examples from FDA observations and warning letters are included to support the need for an effective process.

The Impact of USP Chapter <86> on Endotoxin Testing

December 11, 2024

Pharmaceutical Technology® spoke with Nicola Reid, Associate Director Product Management, Endotoxin Products at Charles River Laboratories, to get her perspective on endotoxin testing and USP’s new Chapter Bacterial Endotoxins Test Using Recombinant Reagents.

Advertisement
Advertisement
Advertisement
Advertisement
x